Q: What is Imbruvica used for?

Imbruvica is used to treat: Chronic lymphocytic leukemia Small lymphocytic lymphoma Mantle cell lymphoma Others

Q: How does Imbruvica work?

Targeting BTK Imbruvica belongs to a class of drugs known as kinase inhibitors. Its primary function is to block the activity of a protein called Bruton's tyrosine kinase (BTK). How it Affects Cancer Cells BTK is found in B cells, which are a type of white blood cell. In certain types of blood cancers, these B cells grow uncontrollably. BTK sends signals that tell these cells to multiply and stay alive. By binding to and inhibiting BTK, Imbruvica disrupts these signals, which can lead to the death of the cancer cells or prevent them from spreading further in the body. Use in Graft-Versus-Host Disease In addition to its role in treating cancer, Imbruvica is used for chronic graft-versus-host disease (cGVHD). In this condition, transplanted immune cells attack the patient's own body. The medication helps by blocking the signaling pathways that contribute to this immune response, potentially reducing inflammation and tissue damage.

Q: What are the active ingredients in Imbruvica?

The active ingredient in Imbruvica is ibrutinib .

Q: What are the side effects of Imbruvica?

Common side effects of Imbruvica may include: diarrhea fatigue muscle pain and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Imbruvica?

Imbruvica belongs to the Bruton's tyrosine kinase inhibitor drug class.

Q: What is the dosage of Imbruvica and how do I take it?

How to Take Imbruvica Imbruvica should be taken exactly as prescribed by a healthcare provider. It is usually taken once a day at approximately the same time. You may take this medication with or without food, but you should drink a full glass of water with each dose. Administration Instructions Tablets and Capsules: Swallow these whole. Do not break, crush, chew, or open them. Oral Suspension: If you are using the liquid form, shake the bottle well for at least 30 seconds before measuring a dose. Use the provided oral dosing syringe to ensure the correct amount is taken. Missed Doses If you miss a dose of Imbruvica, take it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and return to your regular schedule. Do not take extra medicine to make up for a missed dose. Dietary Considerations While taking Imbruvica, you should avoid eating grapefruit or Seville oranges, as well as drinking juice made from these fruits. These products can increase the level of the medication in your blood and may lead to more side effects.

Q: Is Imbruvica safe during pregnancy and breastfeeding?

Pregnancy Risks Imbruvica can cause harm to an unborn baby. Research indicates that exposure to this medication during pregnancy may lead to birth defects or pregnancy loss. Healthcare providers typically require a pregnancy test before starting this medication in individuals who are able to become pregnant. Contraception To prevent pregnancy during and after treatment, effective birth control should be used: Females: Use effective contraception during treatment and for at least 1 month after the final dose. Males: Use effective contraception if your partner is able to become pregnant during treatment and for at least 1 month after the final dose. If you become pregnant or think you might be pregnant while taking this medication, contact your healthcare provider immediately to discuss the potential risks. Breastfeeding It is not known if Imbruvica passes into human breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for at least 1 week after the last dose.

Q: What is the FDA approval status of Imbruvica?

FDA Approval History Imbruvica was first granted FDA approval in 2013. Over the following years, the FDA expanded its approved uses to include several types of B-cell malignancies and chronic graft-versus-host disease (cGVHD). In 2022, the FDA approved the drug for pediatric patients aged 1 year and older with cGVHD, which included the introduction of an oral suspension formulation. Current Approved Indications As of the most recent regulatory updates, Imbruvica is FDA-approved for the treatment of: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Waldenström’s macroglobulinemia. Chronic graft-versus-host disease (cGVHD) after the failure of one or more lines of systemic therapy. In 2020, the FDA specifically approved the combination of ibrutinib with rituximab for the treatment of previously untreated patients with CLL or SLL. Regulatory Status Changes While Imbruvica previously held accelerated approvals for mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), the manufacturer voluntarily withdrew these indications in 2023. This decision followed results from confirmatory clinical trials that did not meet the requirements to convert the accelerated approvals to full approvals.

Question 1

What is Imbruvica?

Accepted Answer

Imbruvica is a kinase inhibitor that functions as a targeted therapy. It works by blocking the action of a specific protein called Bruton's tyrosine kinase, which is involved in the growth and survival of certain abnormal cells.

By interfering with these cellular signaling pathways, the medication helps to control the progression of various conditions. This mechanism allows the treatment to focus on the biological drivers of the disease rather than affecting all rapidly dividing cells.

Question 2

What is Imbruvica used for?

Accepted Answer

Imbruvica is used to treat:

Chronic lymphocytic leukemia
Small lymphocytic lymphoma
Mantle cell lymphoma
Others

Question 3

How does Imbruvica work?

Accepted Answer

Targeting BTK

Imbruvica belongs to a class of drugs known as kinase inhibitors. Its primary function is to block the activity of a protein called Bruton's tyrosine kinase (BTK).

How it Affects Cancer Cells

BTK is found in B cells, which are a type of white blood cell. In certain types of blood cancers, these B cells grow uncontrollably. BTK sends signals that tell these cells to multiply and stay alive. By binding to and inhibiting BTK, Imbruvica disrupts these signals, which can lead to the death of the cancer cells or prevent them from spreading further in the body.

Use in Graft-Versus-Host Disease

In addition to its role in treating cancer, Imbruvica is used for chronic graft-versus-host disease (cGVHD). In this condition, transplanted immune cells attack the patient's own body. The medication helps by blocking the signaling pathways that contribute to this immune response, potentially reducing inflammation and tissue damage.

Question 4

What are the active ingredients in Imbruvica?

Accepted Answer

The active ingredient in Imbruvica is ibrutinib.

Question 5

What are the side effects of Imbruvica?

Accepted Answer

Common side effects of Imbruvica may include:

diarrhea
fatigue
muscle pain
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Imbruvica?

Accepted Answer

Imbruvica belongs to the Bruton's tyrosine kinase inhibitor drug class.

Question 7

What is the dosage of Imbruvica and how do I take it?

Accepted Answer

How to Take Imbruvica

Imbruvica should be taken exactly as prescribed by a healthcare provider. It is usually taken once a day at approximately the same time. You may take this medication with or without food, but you should drink a full glass of water with each dose.

Administration Instructions

Tablets and Capsules: Swallow these whole. Do not break, crush, chew, or open them.
Oral Suspension: If you are using the liquid form, shake the bottle well for at least 30 seconds before measuring a dose. Use the provided oral dosing syringe to ensure the correct amount is taken.

Missed Doses

If you miss a dose of Imbruvica, take it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and return to your regular schedule. Do not take extra medicine to make up for a missed dose.

Dietary Considerations

While taking Imbruvica, you should avoid eating grapefruit or Seville oranges, as well as drinking juice made from these fruits. These products can increase the level of the medication in your blood and may lead to more side effects.

Question 8

Is Imbruvica safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy Risks

Imbruvica can cause harm to an unborn baby. Research indicates that exposure to this medication during pregnancy may lead to birth defects or pregnancy loss. Healthcare providers typically require a pregnancy test before starting this medication in individuals who are able to become pregnant.

Contraception

To prevent pregnancy during and after treatment, effective birth control should be used:

Females: Use effective contraception during treatment and for at least 1 month after the final dose.
Males: Use effective contraception if your partner is able to become pregnant during treatment and for at least 1 month after the final dose.

If you become pregnant or think you might be pregnant while taking this medication, contact your healthcare provider immediately to discuss the potential risks.

Breastfeeding

It is not known if Imbruvica passes into human breast milk. Because of the potential for serious side effects in a nursing infant, breastfeeding is not recommended during treatment and for at least 1 week after the last dose.

Question 9

What forms and strengths does Imbruvica come in?

Accepted Answer

Imbruvica is administered orally and comes in the following forms:

Capsules: Hard-shell capsules for oral use.
Tablets: Film-coated tablets for oral use.
Oral Suspension: A liquid formulation used for oral administration.

The oral suspension is used for certain patient populations, including pediatric patients, and provides an alternative for those who may have difficulty swallowing solid dosage forms.

Question 10

What is the FDA approval status of Imbruvica?

Accepted Answer

FDA Approval History

Imbruvica was first granted FDA approval in 2013. Over the following years, the FDA expanded its approved uses to include several types of B-cell malignancies and chronic graft-versus-host disease (cGVHD). In 2022, the FDA approved the drug for pediatric patients aged 1 year and older with cGVHD, which included the introduction of an oral suspension formulation.

Current Approved Indications

As of the most recent regulatory updates, Imbruvica is FDA-approved for the treatment of:

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Waldenström’s macroglobulinemia.
Chronic graft-versus-host disease (cGVHD) after the failure of one or more lines of systemic therapy.

In 2020, the FDA specifically approved the combination of ibrutinib with rituximab for the treatment of previously untreated patients with CLL or SLL.

Regulatory Status Changes

While Imbruvica previously held accelerated approvals for mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), the manufacturer voluntarily withdrew these indications in 2023. This decision followed results from confirmatory clinical trials that did not meet the requirements to convert the accelerated approvals to full approvals.

Question 11

What should I know about Imbruvica and cost?

Accepted Answer

Insurance and Prior Authorization

Imbruvica is a specialty medication, which means it is often more expensive than standard prescriptions. Most insurance plans, including Medicare and private insurance, require prior authorization before they will cover the cost. This process involves your doctor providing documentation to the insurance company to prove the medication is medically necessary.

Financial Assistance Programs

Because of the high cost of this treatment, there are several options that may help reduce out-of-pocket expenses:

Manufacturer Co-pay Cards: Patients with commercial insurance may be eligible for co-pay savings programs provided by the drug manufacturer.
Patient Assistance Programs: For individuals without insurance or those who are underinsured, non-profit foundations or the manufacturer may offer programs to provide the medication at a lower cost or for free.
Specialty Pharmacy Services: Since Imbruvica is usually dispensed through specialty pharmacies, these providers often have staff dedicated to helping patients navigate insurance claims and find financial aid.

It is important to discuss financial concerns with your healthcare provider or a social worker, as they can help identify resources to assist with the cost of therapy.

Imbruvica

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Imbruvica

Hospitals.net Disclosure